Cagrilintide
Long-acting amylin analogue for appetite regulation and weight management.
For research purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm these products will be used for legitimate research purposes.
About Cagrilintide
Cagrilintide is a long-acting analogue of amylin, the hormone co-secreted with insulin that signals satiety and slows gastric emptying. It acts on amylin and calcitonin receptors to reduce food intake and is studied both alone and paired with GLP-1 agonists (e.g. the CagriSema combination with semaglutide). Its once-weekly profile targets appetite through a mechanism distinct from, and complementary to, incretin-based therapies.
Key Benefits
- Reduces appetite via amylin-receptor signaling
- Slows gastric emptying to prolong satiety
- Complementary mechanism to GLP-1 agonists
- Once-weekly dosing convenience
Set a goal (top of the page) to see how Cagrilintide scores against it, and what the better-evidenced alternatives are.
Category Ratings
How to Take
Common Side Effects
- Nausea
- Vomiting
- Reduced appetite
- Injection site reactions
- Constipation
Legal & Regulatory Status
Investigational — in Phase 3 trials (Novo Nordisk), including the CagriSema combination with semaglutide. Not FDA-approved.
Safety and regulatory details for FDA-approved compounds are drawn from the official product label via openFDA; clinical development status reflects ClinicalTrials.gov. This information is provided for research reference, is not endorsed by the FDA, and may not be complete or current.
Research & Sources
Sources are selected for reliability (peer-reviewed literature, openFDA, ClinicalTrials.gov) but this is a research summary, not medical advice, and may not be exhaustive.